PrP
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
15 Aug 2024
15 Aug 2024
Historique:
received:
23
05
2024
accepted:
07
08
2024
revised:
02
08
2024
medline:
16
8
2024
pubmed:
16
8
2024
entrez:
15
8
2024
Statut:
aheadofprint
Résumé
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) benefit from treatment with tyrosine kinase inhibitors (TKI) targeting EGFR. Despite improvements in patient care, especially with the 3rd generation TKI osimertinib, disease relapse is observed in all patients. Among the various processes involved in TKI resistance, epithelial-to-mesenchymal transition (EMT) is far from being fully characterized. We hypothesized that the cellular prion protein PrP
Identifiants
pubmed: 39147880
doi: 10.1038/s41388-024-03130-0
pii: 10.1038/s41388-024-03130-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Institut National de la Santé et de la Recherche Médicale (National Institute of Health and Medical Research)
ID : U1138
Organisme : Institut National de la Santé et de la Recherche Médicale (National Institute of Health and Medical Research)
ID : U1138
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
pubmed: 33538338
doi: 10.3322/caac.21660
Yang C-Y, Yang JC-H, Yang P-C. Precision management of advanced non-small cell lung cancer. Annu Rev Med. 2020;71:117–36.
pubmed: 31986082
doi: 10.1146/annurev-med-051718-013524
Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17:637–58.
pubmed: 29068003
doi: 10.1038/nrc.2017.84
Passaro A, Jänne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2:377–91.
pubmed: 35122001
doi: 10.1038/s43018-021-00195-8
Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26.
pubmed: 21430269
pmcid: 3132801
doi: 10.1126/scitranslmed.3002003
Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012;44:852–60.
pubmed: 22751098
pmcid: 3408577
doi: 10.1038/ng.2330
Weng C-H, Chen L-Y, Lin Y-C, Shih J-Y, Lin Y-C, Tseng R-Y, et al. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. Oncogene. 2019;38:455–68.
pubmed: 30111817
doi: 10.1038/s41388-018-0454-2
Aissa AF, Islam ABMMK, Ariss MM, Go CC, Rader AE, Conrardy RD, et al. Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. Nat Commun. 2021;12:1628.
pubmed: 33712615
pmcid: 7955121
doi: 10.1038/s41467-021-21884-z
Bronte G, Bravaccini S, Bronte E, Burgio MA, Rolfo C, Delmonte A, et al. Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer. Biol Rev Camb Philos Soc. 2018;93:1735–46.
pubmed: 29671943
doi: 10.1111/brv.12416
Zhu X, Chen L, Liu L, Niu X. EMT-mediated acquired EGFR-TKI resistance in NSCLC: mechanisms and strategies. Front Oncol. 2019;9:1044.
pubmed: 31681582
pmcid: 6798878
doi: 10.3389/fonc.2019.01044
Raoof S, Mulford IJ, Frisco-Cabanos H, Nangia V, Timonina D, Labrot E, et al. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene. 2019;38:6399–413.
pubmed: 31324888
pmcid: 6742540
doi: 10.1038/s41388-019-0887-2
Yochum ZA, Cades J, Wang H, Chatterjee S, Simons BW, O’Brien JP, et al. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene 2019;38:656–70.
pubmed: 30171258
doi: 10.1038/s41388-018-0482-y
Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, et al. A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci Transl Med. 2020;12:eaaz4589.
pubmed: 32878980
pmcid: 8269000
doi: 10.1126/scitranslmed.aaz4589
Tulchinsky E, Demidov O, Kriajevska M, Barlev NA, Imyanitov E. EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer. Biochim Biophys Acta Rev Cancer. 2019;1871:29–39.
pubmed: 30419315
doi: 10.1016/j.bbcan.2018.10.003
Mouillet-Richard S, Ghazi A, Laurent-Puig P. The cellular prion protein and the hallmarks of cancer. Cancers. 2021;13:5032.
pubmed: 34638517
pmcid: 8508458
doi: 10.3390/cancers13195032
Le Corre D, Ghazi A, Balogoun R, Pilati C, Aparicio T, Martin-Lannerée S, et al. The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. EBioMedicine. 2019;46:94–104.
pubmed: 31377347
pmcid: 6710984
doi: 10.1016/j.ebiom.2019.07.036
Lin S-C, Lin C-H, Shih N-C, Liu H-L, Wang W-C, Lin K-Y, et al. Cellular prion protein transcriptionally regulated by NFIL3 enhances lung cancer cell lamellipodium formation and migration through JNK signaling. Oncogene. 2020;39:385–98.
pubmed: 31477838
doi: 10.1038/s41388-019-0994-0
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.
pubmed: 22460905
pmcid: 3320027
doi: 10.1038/nature11003
Garinet S, Didelot A, Denize T, Perrier A, Beinse G, Leclere J-B, et al. Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC. Br J Cancer. 2021;125:1544–51.
pubmed: 34642464
pmcid: 8609001
doi: 10.1038/s41416-021-01568-7
Chen Y-J, Roumeliotis TI, Chang Y-H, Chen C-T, Han C-L, Lin M-H, et al. Proteogenomics of non-smoking lung cancer in East Asia delineates molecular signatures of pathogenesis and progression. Cell. 2020;182:226–44.e17.
pubmed: 32649875
doi: 10.1016/j.cell.2020.06.012
Lehtiö J, Arslan T, Siavelis I, Pan Y, Socciarelli F, Berkovska O, et al. Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms. Nat Cancer. 2021;2:1224–42.
pubmed: 34870237
pmcid: 7612062
doi: 10.1038/s43018-021-00259-9
Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin Cancer Res J Am Assoc Cancer Res. 2016;22:609–20.
doi: 10.1158/1078-0432.CCR-15-0876
de Reyniès A, Jaurand M-C, Renier A, Couchy G, Hysi I, Elarouci N, et al. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res. 2014;20:1323–34.
pubmed: 24443521
doi: 10.1158/1078-0432.CCR-13-2429
Garinet S, Didelot A, Marisa L, Beinse G, Sroussi M, Le Pimpec-Barthes F, et al. A novel Chr1-miR-200 driven whole transcriptome signature shapes tumor immune microenvironment and predicts relapse in early-stage lung adenocarcinoma. J Transl Med. 2023;21:324.
pubmed: 37189151
pmcid: 10184345
doi: 10.1186/s12967-023-04086-7
Sun Y, Daemen A, Hatzivassiliou G, Arnott D, Wilson C, Zhuang G, et al. Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells. Cancer Metab. 2014;2:20.
pubmed: 25379179
pmcid: 4221711
doi: 10.1186/2049-3002-2-20
Martin-Lannerée S, Halliez S, Hirsch TZ, Hernandez-Rapp J, Passet B, Tomkiewicz C, et al. The cellular prion protein controls notch signaling in neural stem/progenitor cells. Stem Cells. 2017;35:754–65.
pubmed: 27641601
doi: 10.1002/stem.2501
Wang Y, Yu S, Huang D, Cui M, Hu H, Zhang L, et al. Cellular prion protein mediates pancreatic cancer cell survival and invasion through association with and enhanced signaling of Notch1. Am J Pathol. 2016;186:2945–56.
pubmed: 27639164
pmcid: 6667968
doi: 10.1016/j.ajpath.2016.07.010
Derynck R, Muthusamy BP, Saeteurn KY. Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. Curr Opin Cell Biol. 2014;31:56–66.
pubmed: 25240174
pmcid: 4657734
doi: 10.1016/j.ceb.2014.09.001
Hori K, Sen A, Artavanis-Tsakonas S. Notch signaling at a glance. J Cell Sci. 2013;126:2135–40.
pubmed: 23729744
pmcid: 3672934
Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 2011;19:192–205.
pubmed: 21295524
pmcid: 3040415
doi: 10.1016/j.ccr.2010.12.022
Manderfield LJ, High FA, Engleka KA, Liu F, Li L, Rentschler S, et al. Notch activation of Jagged1 contributes to the assembly of the arterial wall. Circulation. 2012;125:314–23.
pubmed: 22147907
doi: 10.1161/CIRCULATIONAHA.111.047159
Ghazi A, Le Corre D, Pilati C, Taieb J, Aparicio T, Didelot A, et al. Prognostic value of the PrPC-ILK-IDO1 axis in the mesenchymal colorectal cancer subtype. Oncoimmunology. 2021;10:1940674.
pubmed: 34249475
pmcid: 8244775
doi: 10.1080/2162402X.2021.1940674
Li H, Zhang J, Ke J-R, Yu Z, Shi R, Gao S-S, et al. Pro-prion, as a membrane adaptor protein for E3 ligase c-Cbl, facilitates the ubiquitination of IGF-1R, promoting melanoma metastasis. Cell Rep. 2022;41:111834.
pubmed: 36543142
doi: 10.1016/j.celrep.2022.111834
Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, et al. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 2006;66:393–403.
pubmed: 16397254
doi: 10.1158/0008-5472.CAN-05-2304
Jiang H, Zhou C, Zhang Z, Wang Q, Wei H, Shi W, et al. Jagged1-Notch1-deployed tumor perivascular niche promotes breast cancer stem cell phenotype through Zeb1. Nat Commun. 2020;11:5129.
pubmed: 33046710
pmcid: 7552407
doi: 10.1038/s41467-020-18860-4
Maciaczyk D, Picard D, Zhao L, Koch K, Herrera-Rios D, Li G, et al. CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells. Br J Cancer. 2017;117:102–12.
pubmed: 28571041
pmcid: 5520214
doi: 10.1038/bjc.2017.157
Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Investig. 2009;119:3000–10.
pubmed: 19759520
pmcid: 2752070
Pallier K, Cessot A, Côté J-F, Just P-A, Cazes A, Fabre E, et al. TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma. PLoS ONE. 2012;7:e29954.
pubmed: 22272264
pmcid: 3260187
doi: 10.1371/journal.pone.0029954
Andreu-Agullo C, Morante-Redolat JM, Delgado AC, Farinas I. Vascular niche factor PEDF modulates Notch-dependent stemness in the adult subependymal zone. Nat Neurosci. 2009;12:1514–23.
pubmed: 19898467
doi: 10.1038/nn.2437
Atkinson CJ, Kawamata F, Liu C, Ham S, Győrffy B, Munn AL, et al. EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer. Mol Oncol. 2019;13:725–37.
pubmed: 30478887
pmcid: 6441932
doi: 10.1002/1878-0261.12411
Zhang X, Maity TK, Ross KE, Qi Y, Cultraro CM, Bahta M, et al. Alterations in the global proteome and phosphoproteome in third generation EGFR TKI resistance reveal drug targets to circumvent resistance. Cancer Res. 2021;81:3051–66.
pubmed: 33727228
pmcid: 8182571
doi: 10.1158/0008-5472.CAN-20-2435
Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, et al. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell. 2020;37:104–22.e12.
pubmed: 31935369
pmcid: 7146079
doi: 10.1016/j.ccell.2019.12.006
Gogleva A, Polychronopoulos D, Pfeifer M, Poroshin V, Ughetto M, Martin MJ, et al. Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer. Nat Commun. 2022;13:1667.
pubmed: 35351890
pmcid: 8964738
doi: 10.1038/s41467-022-29292-7
Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, et al. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell. 2020;182:1232–51.e22.
pubmed: 32822576
pmcid: 7484178
doi: 10.1016/j.cell.2020.07.017
Aguzzi A, Baumann F, Bremer J. The prion’s elusive reason for being. Annu Rev Neurosci. 2008;31:439–77.
pubmed: 18558863
doi: 10.1146/annurev.neuro.31.060407.125620
Karachaliou N, Cardona AF, Bracht JWP, Aldeguer E, Drozdowskyj A, Fernandez-Bruno M, et al. Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC). EBioMedicine. 2019;39:207–14.
pubmed: 30473379
doi: 10.1016/j.ebiom.2018.11.036
Zhang T, Guo L, Creighton CJ, Lu Q, Gibbons DL, Yi ES, et al. A genetic cell context-dependent role for ZEB1 in lung cancer. Nat Commun. 2016;7:12231.
pubmed: 27456471
pmcid: 4963474
doi: 10.1038/ncomms12231
Brabletz S, Bajdak K, Meidhof S, Burk U, Niedermann G, Firat E, et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J. 2011;30:770–82.
pubmed: 21224848
pmcid: 3041948
doi: 10.1038/emboj.2010.349
Mouillet-Richard S, Gougelet A, Passet B, Brochard C, Le Corre D, Pitasi CL, et al. Wnt, glucocorticoid and cellular prion protein cooperate to drive a mesenchymal phenotype with poor prognosis in colon cancer. J Transl Med. 2024;22:337.
pubmed: 38589873
pmcid: 11003154
doi: 10.1186/s12967-024-05164-0
Llorens F, Carulla P, Villa A, Torres JM, Fortes P, Ferrer I, et al. PrP(C) regulates epidermal growth factor receptor function and cell shape dynamics in Neuro2a cells. J Neurochem. 2013;127:124–38.
pubmed: 23638794
doi: 10.1111/jnc.12283
Martellucci S, Manganelli V, Santacroce C, Santilli F, Piccoli L, Sorice M, et al. Role of Prion protein-EGFR multimolecular complex during neuronal differentiation of human dental pulp-derived stem cells. Prion. 2018;12:117–26.
pubmed: 29644924
pmcid: 6016517
doi: 10.1080/19336896.2018.1463797
Groveman BR, Schwarz B, Bohrnsen E, Foliaki ST, Carroll JA, Wood AR, et al. A PrP EGFR signaling axis controls neural stem cell senescence through modulating cellular energy pathways. J Biol Chem. 2023;299:105319.
pubmed: 37802314
pmcid: 10641666
doi: 10.1016/j.jbc.2023.105319
Solis GP, Schrock Y, Hulsbusch N, Wiechers M, Plattner H, Stuermer CA. Reggies/flotillins regulate E-cadherin-mediated cell contact formation by affecting EGFR trafficking. Mol Biol Cell. 2012;23:1812–25.
pubmed: 22438585
pmcid: 3350547
doi: 10.1091/mbc.e11-12-1006
Mouillet-Richard S, Martin-Lannerée S, Le Corre D, Hirsch TZ, Ghazi A, Sroussi M, et al. A proof of concept for targeting the PrPC - Amyloid β peptide interaction in basal prostate cancer and mesenchymal colon cancer. Oncogene. 2022;41:4397–404.
pubmed: 35962130
pmcid: 9481457
doi: 10.1038/s41388-022-02430-7
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.
pubmed: 23104886
doi: 10.1093/bioinformatics/bts635
Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–50.
doi: 10.1038/nature13385
Pécuchet N, Zonta E, Didelot A, Combe P, Thibault C, Gibault L, et al. Base-position error rate analysis of next-generation sequencing applied to circulating tumor DNA in non-small cell lung cancer: a prospective study. PLoS Med. 2016;13:e1002199.
pubmed: 28027313
pmcid: 5189949
doi: 10.1371/journal.pmed.1002199